Javascript must be enabled to continue!
1599-P: Regulation of Mitochondrial Dynamics Ameliorates Hepatic Steatosis through TFEB Activation
View through CrossRef
Nonalcoholic fatty liver disease (NAFLD) is a common cause of liver disease that is closely related to metabolic syndromes, obesity, and type 2diabetes. There is strong evidence that mitochondrial dysfunction plays a significant role in the development and progression of NAFLD. Recently, growing evidence suggests that the TFEB plays a pivotal role in mitochondrial dynamics. In this study, we investigated that mitochondrial dynamics play the potential role and mechanisms of TFEB in the amelioration of NAFLD. FFA increased expression of mitochondrial fission proteins p-Drp1, Fis1 and decreased expression of fusion proteins OPA1, Mfn2 and inhibition of TFEB activation. Mitotracker stain significantly increased in the proportion of cells with fragmented mitochondria in FFA-treated cells. HFD-fed mice displayed histology consistent with pathological hepatic steatosis. EM analysis indicated that HFD-fed mitochondria tended to be shorter and more round than ND-fed mitochondria. Western blot analyses reveal increased expression of the fission proteins, p-Drp1, Fis1, and significantly decreased in the fusion protein, Mfn2 and OPA1 in HFD-fed group. In vivo Tfeb knockout dramatically increased hepatic fat accumulation, liver ballooning in HFD-fed mice. EM analysis showed that HFD-fed Tfeb knockout mice had more rounded and swollen mitochondria, indicating that TFEB was dependent on the regulation of mitochondrial fragmentation. In vivo Tfeb knockout reveal significantly increased expression of the fission proteins in HFD-fed group. To demonstrated the direct regulatory mechanism of mitochondrial dynamics and TFEB activation, we used siRNA DRP1 and Mdivi-1. Inhibition of Drp1 promotes mitochondrial fusion, increased expression of fusion protein and reduced fat accumulation and activated TFEB. These results suggest a role in improving hepatic steatosis through regulation of TFEB-mediated mitochondrial dynamics in NAFLD.
Disclosure
J.Yoo: Other Relationship; American Diabetes Association. Y.Hwang: None.
Funding
National Research Foundation of Korea (2022R1I1A1A01069899)
Title: 1599-P: Regulation of Mitochondrial Dynamics Ameliorates Hepatic Steatosis through TFEB Activation
Description:
Nonalcoholic fatty liver disease (NAFLD) is a common cause of liver disease that is closely related to metabolic syndromes, obesity, and type 2diabetes.
There is strong evidence that mitochondrial dysfunction plays a significant role in the development and progression of NAFLD.
Recently, growing evidence suggests that the TFEB plays a pivotal role in mitochondrial dynamics.
In this study, we investigated that mitochondrial dynamics play the potential role and mechanisms of TFEB in the amelioration of NAFLD.
FFA increased expression of mitochondrial fission proteins p-Drp1, Fis1 and decreased expression of fusion proteins OPA1, Mfn2 and inhibition of TFEB activation.
Mitotracker stain significantly increased in the proportion of cells with fragmented mitochondria in FFA-treated cells.
HFD-fed mice displayed histology consistent with pathological hepatic steatosis.
EM analysis indicated that HFD-fed mitochondria tended to be shorter and more round than ND-fed mitochondria.
Western blot analyses reveal increased expression of the fission proteins, p-Drp1, Fis1, and significantly decreased in the fusion protein, Mfn2 and OPA1 in HFD-fed group.
In vivo Tfeb knockout dramatically increased hepatic fat accumulation, liver ballooning in HFD-fed mice.
EM analysis showed that HFD-fed Tfeb knockout mice had more rounded and swollen mitochondria, indicating that TFEB was dependent on the regulation of mitochondrial fragmentation.
In vivo Tfeb knockout reveal significantly increased expression of the fission proteins in HFD-fed group.
To demonstrated the direct regulatory mechanism of mitochondrial dynamics and TFEB activation, we used siRNA DRP1 and Mdivi-1.
Inhibition of Drp1 promotes mitochondrial fusion, increased expression of fusion protein and reduced fat accumulation and activated TFEB.
These results suggest a role in improving hepatic steatosis through regulation of TFEB-mediated mitochondrial dynamics in NAFLD.
Disclosure
J.
Yoo: Other Relationship; American Diabetes Association.
Y.
Hwang: None.
Funding
National Research Foundation of Korea (2022R1I1A1A01069899).
Related Results
TFEB signaling attenuates NLRP3‐driven inflammatory responses in severe asthma
TFEB signaling attenuates NLRP3‐driven inflammatory responses in severe asthma
AbstractBackgroundNLRP3‐driven inflammatory responses by circulating and lung‐resident monocytes are critical drivers of asthma pathogenesis. Autophagy restrains NLRP3‐induced mono...
Differential effects of systemic immune inflammation indices on hepatic steatosis and hepatic fibrosis: evidence from NHANES 1999-2018
Differential effects of systemic immune inflammation indices on hepatic steatosis and hepatic fibrosis: evidence from NHANES 1999-2018
Abstract
Background
Several studies have demonstrated that systemic immune inflammation index (SII) has a positive relationship with hepatic steatosis. However, it is lack...
TFEB Signalling-Related MicroRNAs and Autophagy
TFEB Signalling-Related MicroRNAs and Autophagy
The oncogenic Transcription Factor EB (TFEB), a member of MITF-TFE family, is known to be the most important regulator of the transcription of genes responsible for the control of ...
Melatonin Ameliorates the Progression of Alzheimer’s Disease by Inducing TFEB Nuclear Translocation, Promoting Mitophagy, and Regulating NLRP3 Inflammasome Activity
Melatonin Ameliorates the Progression of Alzheimer’s Disease by Inducing TFEB Nuclear Translocation, Promoting Mitophagy, and Regulating NLRP3 Inflammasome Activity
Background. The NLRP3 inflammasome is overactivated in the brains of APP/PS1 transgenic mice and AD patients, and mitophagy has an obvious negative regulatory role on NLRP3 inflamm...
<b>DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy</b>
<b>DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy</b>
<p dir="ltr">G protein-coupled receptor 119 (GPR119) is predominantly expressed in pancreatic β-cells, enteroendocrine cells, and the liver. It is a novel therapeutic for dys...
<b>DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy</b>
<b>DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy</b>
<p dir="ltr">G protein-coupled receptor 119 (GPR119) is predominantly expressed in pancreatic β-cells, enteroendocrine cells, and the liver. It is a novel therapeutic for dys...
Correlation Between COVID-19 Severity, Body Mass Index and Hepatic Steatosis: A Retrograde Cohort Study
Correlation Between COVID-19 Severity, Body Mass Index and Hepatic Steatosis: A Retrograde Cohort Study
Abstract
Background Obesity and fatty liver steatosis are already considered metabolic risk factors that may aggravate the severity of COVID-19. This study aims to investig...
CRISPR activation of
Tfeb
, a master regulator of autophagy and lysosomal biogenesis, in osteoblast lineage cells increases bone mass and strength
CRISPR activation of
Tfeb
, a master regulator of autophagy and lysosomal biogenesis, in osteoblast lineage cells increases bone mass and strength
ABSTRACT
Autophagy is a recycling pathway in which damaged or dysfunctional proteins, protein aggregates, and organelles are delivered to lysosom...

